Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

Patients with newly diagnosed, pathologically confirmed NK/T-cell lymphoma of stage III-IV treated with XCOPL regimen. 3 weeks for a cycle, with a total of 6-8 cycles.

Trial Details

NCT ID
NCT05833893
Phase
PHASE2
Sponsor
Chinese PLA General Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • XPO1 inhibitor
Locations (sample)
  • Beijing, Haidian, China|39.9075,116.39723

Key Eligibility Criteria

  • Age≥14 years, male or female;
  • Pathologically confirmed newly diagnosed NK/T cell lymphoma according to WHO classification criteria 2016;
  • At least one measurable lesion, defined as bidimensionally measurable, intranodal lesion \> 1.5 cm in short axis and extranodal lesion \> 1.0 cm in…
  • ECOG score 0\~2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →